Diclofenac Potassium |
Cataflam |
Clinical Trial: Antiproteinuric Efficacy of Losartan Potassium in Patients with Non-Diabetic Proteinuric Renal Diseases
This study is no longer recruiting patients.
|
Purpose
Antiproteinuric Efficacy of Losartan Potassium in Patients with Non-Diabetic Proteinuric Renal Diseases.
| Condition | Intervention | Phase |
|---|---|---|
| Renal disorder | Drug: MK0954, losartan potassium | Phase IV |
MedlinePlus related topics: Kidney Diseases
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Efficacy Study
Further Study Details:
Study start: January 2000
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Males or females at least 18 years of age with non-diabetic proteinuric renal diseases
Location Information
Spain
Merck Sharp & Dohme De Espana, S.A.E., Madrid, 28027, Spain
Study chairs or principal investigators
Medical Monitor, Study Director, Merck
More Information
Study ID Numbers: 2005_058
Last Updated: August 31, 2005
Record first received: August 30, 2005
ClinicalTrials.gov Identifier: NCT00140985
Health Authority: Spain: Ministry of Health
ClinicalTrials.gov processed this record on 2005-09-13
Last Updated: August 31, 2005
Record first received: August 30, 2005
ClinicalTrials.gov Identifier: NCT00140985
Health Authority: Spain: Ministry of Health
ClinicalTrials.gov processed this record on 2005-09-13
Resources
- Cataflam (Drug Digest)
- Diclofenac Potassium (Drug Digest)

Not Signed In -

